Developer docs
API playgroundTry for free, no card

Search company profiles

Biocorp

Full company profile

uuid003dx2p

Namestring
Biocorp
Legal namestring
Biocorp
Websiteurl
biocorp.fr
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Biocorp is a French medical device company that designs and manufactures connected drug delivery devices, combining precision plastics engineering with digital health sensor technology. The company was founded in 1997, is headquartered in Issoire, France, and operates two complementary sites: Clermont-Ferrand for development, innovation, and support functions, and Issoire for production and quality. The company employs approximately 105 people and is publicly listed under the ticker ALCOR on Euronext Paris, though it was acquired by Novo Nordisk in June 2023 for $178 million and now operates as a wholly-owned subsidiary within Novo Nordisk's digital health portfolio.

The company's product portfolio centers on two FDA-cleared connected devices. The Mallya insulin pen sensor is a smart connected sensor that attaches to insulin pens and received FDA approval in January 2023 for use with both insulin and GLP-1 receptor agonist pens. SoloSmart is a connected drug delivery device that received FDA 510(k) clearance in January 2024, extending the platform beyond diabetes-specific applications. The underlying technology integrates proprietary sensor hardware with connectivity for medication adherence tracking and remote monitoring, targeting the digital health and telehealth needs of chronic disease management.

Biocorp operates an OEM/embedded go-to-market model, supplying connected devices to pharmaceutical partners for integration into their drug delivery ecosystems. Revenue is generated through hardware sales of connected medical devices. Prior to the Novo Nordisk acquisition, the company served pharmaceutical companies in the diabetes care vertical as a B2B supplier. Post-acquisition, distribution is channeled through Novo Nordisk's global pharmaceutical network, positioning Biocorp's products within the diabetes franchise of one of the world's largest insulin and GLP-1 manufacturers. Pricing is not publicly disclosed and the customer base is narrow, with concentration risk in a small number of pharmaceutical OEM relationships.

Short descriptiontext

Biocorp designs and manufactures connected medical devices combining precision engineering with digital health sensor technology, including the FDA-cleared Mallya insulin pen sensor and SoloSmart connected drug delivery device. It supplies these as an OEM to pharmaceutical partners, operating as a wholly-owned subsidiary of Novo Nordisk following a 2023 acquisition.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersIssoire, France
HQ citystring
Issoire
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
connected medical devices, drug delivery systems, insulin pen sensors, medical device manufacturing, digital health devices
Industry3 codes
PRIMARYHLAHAIAM
Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAHAD
Smart Insulin Pens & Connected Pen Caps
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
NAICS code1 code
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Connected Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Connected Medical Device Manufacturing
TypeHardware Sales
Description

Design and manufacture of connected medical devices, operating as a wholly-owned subsidiary of Novo Nordisk following the June 2023 acquisition

biocorpsys.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Mallya
Description

Smart connected insulin pen sensor for diabetes management

biocorpsys.com
+1 more record
Core offering1 text field

Biocorp designs and manufactures connected medical devices that combine precision plastics engineering with digital health technologies, including the Mallya smart insulin pen sensor (FDA-approved January 2023) and the SoloSmart connected drug delivery device (FDA 510(k) cleared January 2024). The company supplies these devices to pharmaceutical partners on an OEM/embedded basis for integration into their drug delivery ecosystems, with end-to-end capabilities spanning R&D, manufacturing, and final packaging across its Clermont-Ferrand and Issoire sites in France.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Mallya insulin pen sensor received FDA approval for use with insulin and GLP-1 receptor agonist pens
Product overview1 text field

Biocorp designs and manufactures connected medical devices combining precision engineering with digital health technologies. The company operates two product lines: the Mallya Insulin Pen Sensor (FDA-approved smart sensor for insulin/GLP-1 pens) and SoloSmart (FDA 510(k)-cleared connected drug delivery device). Biocorp employs 105 people across two sites in France (Clermont-Ferrand for development/innovation and Issoire for manufacturing/quality), offering end-to-end capabilities from R&D through final packaging.

Product and service2 records
1Mallya Insulin Pen Sensor
CategoryConnected Drug Delivery Device
Description

A smart connected device sensor that attaches to insulin pens, providing digital health monitoring and data tracking for diabetes management. Received FDA approval in January 2023 for use with insulin and GLP-1 receptor agonist pens. Targeted at pharmaceutical partners for integration with their diabetes therapy delivery systems.

2SoloSmart
CategoryConnected Drug Delivery Device
Description

A connected drug delivery device that received FDA 510(k) clearance in January 2024, designed to enhance medication adherence and enable remote patient monitoring through digital connectivity. Targeted at pharmaceutical partners for chronic disease management applications.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Bigfoot Biomedical
TypeEmerging player
Description

US-based emerging player developing smart pen caps and connected insulin delivery systems, with a similar product architecture and target use case to Biocorp's Mallya though at earlier commercial scale.

TypeBroad incumbent
Description

Leader in continuous glucose monitoring (CGM) hardware, complementary to Biocorp's Mallya. As CGM expands, Dexcom's data platform overlaps with the connected diabetes ecosystem Biocorp serves, creating both partnership and competitive overlap.

TypeBroad incumbent
Description

US-based connected insulin pump manufacturer (t:slim X2) integrated with CGM and increasingly focused on automated insulin delivery. A broader diabetes device incumbent that addresses the same patient population as Biocorp's connected pen sensors.

TypeDirect peer
Description

Swiss medical device company and one of the closest direct competitors to Biocorp, offering YpsoMate and the SmartPilot/YpsoPod connected pen solutions for insulin and GLP-1 injectable delivery. Both companies supply OEM-style smart sensor add-ons to pharmaceutical partners.

TypeBroad incumbent
Description

Major medical device incumbent with an integrated portfolio spanning insulin pumps, CGM, and smart insulin pen connectivity. Competes with Biocorp in the broader connected diabetes care ecosystem and has substantially greater R&D and commercial resources.

TypeBroad incumbent
Description

Global pharmaceutical company with a major diabetes franchise and prior experience with connected insulin pen initiatives (e.g., partnership with BioCorp's ecosystem). A potential large customer/competitor to Biocorp's smart pen sensor business.

TypeBroad incumbent
Description

Operates the FreeStyle Libre CGM franchise and broader diabetes care portfolio. A large incumbent with overlapping digital health data ambitions relevant to Biocorp's connected injectable therapy positioning.

TypeBroad incumbent
Description

US-based leader in tubeless insulin pump technology (Omnipod). A broader incumbent in connected insulin delivery that competes for the same pharmaceutical and patient mindshare as Biocorp's smart pen sensor products.

9Emperra GmbH
TypeDirect peer
Description

German developer of the Esysta smart insulin pen and connected diabetes management system, directly comparable to Biocorp's Mallya in both technology (pen-attached smart sensor) and customer base (pharmaceutical partners, diabetes patients).

TypeBroad incumbent
Description

Operates the Accu-Chek franchise of blood glucose monitors, insulin pumps, and digital diabetes management tools. A broad incumbent with overlapping interest in connected injectable therapy adherence and remote monitoring.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biocorp

Connected Medical Devicesbiocorp.fr

Biocorp designs and manufactures connected medical devices combining precision engineering with digital health sensor technology, including the FDA-cleared Mallya insulin pen sensor and SoloSmart connected drug delivery device. It supplies these as an OEM to pharmaceutical partners, operating as a wholly-owned subsidiary of Novo Nordisk following a 2023 acquisition.

What Biocorp does

Biocorp is a French medical device company that designs and manufactures connected drug delivery devices, combining precision plastics engineering with digital health sensor technology. The company was founded in 1997, is headquartered in Issoire, France, and operates two complementary sites: Clermont-Ferrand for development, innovation, and support functions, and Issoire for production and quality. The company employs approximately 105 people and is publicly listed under the ticker ALCOR on Euronext Paris, though it was acquired by Novo Nordisk in June 2023 for $178 million and now operates as a wholly-owned subsidiary within Novo Nordisk's digital health portfolio.

The company's product portfolio centers on two FDA-cleared connected devices. The Mallya insulin pen sensor is a smart connected sensor that attaches to insulin pens and received FDA approval in January 2023 for use with both insulin and GLP-1 receptor agonist pens. SoloSmart is a connected drug delivery device that received FDA 510(k) clearance in January 2024, extending the platform beyond diabetes-specific applications. The underlying technology integrates proprietary sensor hardware with connectivity for medication adherence tracking and remote monitoring, targeting the digital health and telehealth needs of chronic disease management.

Biocorp operates an OEM/embedded go-to-market model, supplying connected devices to pharmaceutical partners for integration into their drug delivery ecosystems. Revenue is generated through hardware sales of connected medical devices. Prior to the Novo Nordisk acquisition, the company served pharmaceutical companies in the diabetes care vertical as a B2B supplier. Post-acquisition, distribution is channeled through Novo Nordisk's global pharmaceutical network, positioning Biocorp's products within the diabetes franchise of one of the world's largest insulin and GLP-1 manufacturers. Pricing is not publicly disclosed and the customer base is narrow, with concentration risk in a small number of pharmaceutical OEM relationships.

Biocorp firmographics

Firmographics
Name
Biocorp
Legal name
Biocorp
Website
https://biocorp.fr
Company type
Private
Founded year
2004
Operating status
Acquired
Headcount range
101–250 employees
Short description
Biocorp designs and manufactures connected medical devices combining precision engineering with digital health sensor technology, including the FDA-cleared Mallya insulin pen sensor and SoloSmart connected drug delivery device. It supplies these as an OEM to pharmaceutical partners, operating as a wholly-owned subsidiary of Novo Nordisk following a 2023 acquisition.
Ownership category
akta.pro rank

Biocorp industry classification

Industry
Product category
Connected Medical Devices
NAICS
Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAIAM
Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAHAD
Smart Insulin Pens & Connected Pen Caps
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • Connected medical devices
  • Drug delivery systems
  • Insulin pen sensors
  • Medical device manufacturing
  • Digital health devices

Where Biocorp is headquartered

Location

Headquarters

HQ city
Issoire
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Biocorp business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Connected Medical Device Manufacturing: Design and manufacture of connected medical devices, operating as a wholly-owned subsidiary of Novo Nordisk following the June 2023 acquisition

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Biocorp product offering

Product offering

Core offering

Biocorp designs and manufactures connected medical devices that combine precision plastics engineering with digital health technologies, including the Mallya smart insulin pen sensor (FDA-approved January 2023) and the SoloSmart connected drug delivery device (FDA 510(k) cleared January 2024). The company supplies these devices to pharmaceutical partners on an OEM/embedded basis for integration into their drug delivery ecosystems, with end-to-end capabilities spanning R&D, manufacturing, and final packaging across its Clermont-Ferrand and Issoire sites in France.

Product overview

Biocorp designs and manufactures connected medical devices combining precision engineering with digital health technologies. The company operates two product lines: the Mallya Insulin Pen Sensor (FDA-approved smart sensor for insulin/GLP-1 pens) and SoloSmart (FDA 510(k)-cleared connected drug delivery device). Biocorp employs 105 people across two sites in France (Clermont-Ferrand for development/innovation and Issoire for manufacturing/quality), offering end-to-end capabilities from R&D through final packaging.

Differentiator

Problem solved

Functional benefit

Brands

  • Mallya: Smart connected insulin pen sensor for diabetes management
  • SoloSmart

Products and services

  • Mallya Insulin Pen Sensor A smart connected device sensor that attaches to insulin pens, providing digital health monitoring and data tracking for diabetes management. Received FDA approval in January 2023 for use with insulin and GLP-1 receptor agonist pens. Targeted at pharmaceutical partners for integration with their diabetes therapy delivery systems.
  • SoloSmart A connected drug delivery device that received FDA 510(k) clearance in January 2024, designed to enhance medication adherence and enable remote patient monitoring through digital connectivity. Targeted at pharmaceutical partners for chronic disease management applications.

Quantifiable outcome

  • Mallya insulin pen sensor received FDA approval for use with insulin and GLP-1 receptor agonist pens

Companies that use Biocorp

Customer profile

Segments1 record

Ideal customer profiles1 record

Biocorp technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Biocorp partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Biocorp competitors and assessment

Company assessment

Emerging players

  • Bigfoot Biomedical: US-based emerging player developing smart pen caps and connected insulin delivery systems, with a similar product architecture and target use case to Biocorp's Mallya though at earlier commercial scale.

Broad incumbents

  • Dexcom: Leader in continuous glucose monitoring (CGM) hardware, complementary to Biocorp's Mallya. As CGM expands, Dexcom's data platform overlaps with the connected diabetes ecosystem Biocorp serves, creating both partnership and competitive overlap.
  • Tandem Diabetes Care: US-based connected insulin pump manufacturer (t:slim X2) integrated with CGM and increasingly focused on automated insulin delivery. A broader diabetes device incumbent that addresses the same patient population as Biocorp's connected pen sensors.
  • Medtronic Diabetes: Major medical device incumbent with an integrated portfolio spanning insulin pumps, CGM, and smart insulin pen connectivity. Competes with Biocorp in the broader connected diabetes care ecosystem and has substantially greater R&D and commercial resources.
  • Sanofi Diabetes: Global pharmaceutical company with a major diabetes franchise and prior experience with connected insulin pen initiatives (e.g., partnership with BioCorp's ecosystem). A potential large customer/competitor to Biocorp's smart pen sensor business.
  • Abbott Diabetes Care: Operates the FreeStyle Libre CGM franchise and broader diabetes care portfolio. A large incumbent with overlapping digital health data ambitions relevant to Biocorp's connected injectable therapy positioning.
  • Insulet Corporation: US-based leader in tubeless insulin pump technology (Omnipod). A broader incumbent in connected insulin delivery that competes for the same pharmaceutical and patient mindshare as Biocorp's smart pen sensor products.
  • Roche Diabetes Care: Operates the Accu-Chek franchise of blood glucose monitors, insulin pumps, and digital diabetes management tools. A broad incumbent with overlapping interest in connected injectable therapy adherence and remote monitoring.

Direct peers

  • Ypsomed: Swiss medical device company and one of the closest direct competitors to Biocorp, offering YpsoMate and the SmartPilot/YpsoPod connected pen solutions for insulin and GLP-1 injectable delivery. Both companies supply OEM-style smart sensor add-ons to pharmaceutical partners.
  • Emperra GmbH: German developer of the Esysta smart insulin pen and connected diabetes management system, directly comparable to Biocorp's Mallya in both technology (pen-attached smart sensor) and customer base (pharmaceutical partners, diabetes patients).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

Biocorp social profiles

Digital presence

Biocorp compliance and trust

Trust signal

Compliance2 records

Biocorp financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biocorp leadership team

Management profile

Number of profiles

Profiles1 record

Biocorp funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biocorp M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocorp

What does Biocorp do?

Biocorp designs and manufactures connected medical devices that combine precision plastics engineering with digital health technologies, including the Mallya smart insulin pen sensor (FDA-approved January 2023) and the SoloSmart connected drug delivery device (FDA 510(k) cleared January 2024). The company supplies these devices to pharmaceutical partners on an OEM/embedded basis for integration into their drug delivery ecosystems, with end-to-end capabilities spanning R&D, manufacturing, and final packaging across its Clermont-Ferrand and Issoire sites in France.

Is Biocorp a public or private company?

Biocorp is a private company. It is classified as corporate owned and is currently acquired.

When was Biocorp founded?

Biocorp was founded in 2004. It employs 101 to 250 people.

Where is Biocorp based?

Biocorp is headquartered in Issoire, France, in the Europe region.

How does Biocorp make money?

One revenue line is on record: connected Medical Device Manufacturing.

Who are Biocorp's main competitors?

Bigfoot Biomedical is listed as an emerging player. Broad incumbents are Dexcom, Tandem Diabetes Care, Medtronic Diabetes, Sanofi Diabetes, Abbott Diabetes Care, Insulet Corporation and Roche Diabetes Care. Direct peers are Ypsomed and Emperra GmbH.

Does Biocorp have an API?

No public API is recorded for Biocorp.

What industry is Biocorp in?

Biocorp's product category is Connected Medical Devices. Its primary akta.pro industry code is HLAHAIAM, Drug Delivery Connectivity, Sensors & Digital Add-Ons (Smart Caps/Companion Apps), with a secondary code of HLAHAHAD, Smart Insulin Pens & Connected Pen Caps. Its NAICS code is 3345 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comStructure of the Smart Disposable Medical Device Market, Current Trends, and Key Player AnalysisThe Business Research Company released a market report projecting the smart disposable medical device market to reach $16.1 billion by 2030, growing at a 19.9% CAGR, driven by remote patient monitoring, smart drug adherence technologies, and digital health integration. In June 2023, Novo Nordisk acquired Biocorp for $178 million to strengthen its digital health portfolio with Biocorp's smart connected devices including the Mallya insulin pen sensor, which received FDA approval in January 2023 for use with insulin and GLP-1 receptor agonist pens.openPR.comSegmentation, Major Trends, and Competitive Overview of the Lancing Devices and Equipment MarketThe lancing devices and equipment market is projected to reach $4.98 billion by 2030, growing at a compound annual growth rate of 9.1%, driven by rising demand for home diagnostic solutions, increased focus on patient comfort, and technological advancements in minimally invasive sampling technologies. In October 2023, Denmark-based Novo Nordisk acquired French company Biocorp for $164.5 million to strengthen its portfolio in diabetes care solutions including blood glucose meters, lancing devices, and insulin pumps. In August 2023, Swiss company F. Hoffmann-La Roche AG launched the Accu-Chek Pico, a fully disposable lancing device for people with diabetes.FatposglobalConnected Drug Delivery Devices Market Size, Share, Forecast, 2031A market research report projects the global Connected Drug Delivery Devices Market to grow from USD 0.24 billion in 2021 to USD 1.03 billion by 2031, representing a CAGR of 15.4% during the forecast period. The report identifies connected sensors and Bluetooth technology as the leading product and technology segments respectively, with North America holding over 33% revenue share in 2020 driven by high healthcare expenditure and technology adoption. Key players profiled include Propeller Health, Teva Pharmaceutical Industries Ltd., BIOCORP, Merck KGaA, and others, while market growth drivers include rising IoT penetration and demand for medication adherence solutions.Knowledge Sourcing IntelligencePortable Medical Devices Market Insights: Share, Forecast 2030A market research report projects the global portable medical devices market will grow from $56.50 billion in 2025 to $87.10 billion by 2030, representing a compound annual growth rate of 9.1%. Key growth drivers include rising chronic diseases, expanding elderly populations, technological advancements in wearable and wireless medical devices, and increasing preference for home healthcare settings. The report profiles multiple companies actively launching products in this space, including Samsung, GE Healthcare, Medtronic, Clarius Mobile Health, Max Ventilator, Mobvoi, Biocorp, Novo Nordisk, and SmartCardia.PR NewswireSyringes and Needles Market is Projected to Reach $47.20 Billion by 2029, An Analysis of Industry Outlook & Forecast 2024-2029 - AriztonArizton Advisory & Intelligence published a market research report projecting the global syringes and needles market to reach $47.20 billion by 2029, growing at a CAGR of 7.93% during 2023-2029, driven by the need to prevent needlestick injuries and hospital-acquired infections. Japan is highlighted as a dominant Asia-Pacific market projected to reach $2.46 billion by 2029 with a 9.49% CAGR, attributed to its aging population and high chronic disease prevalence. Notable recent industry developments include Nipro's 2023 launch of a silicone oil-free pre-fillable syringe system, BD's 2022 partnership with Biocorp for connected drug delivery technology, and Terumo Corporation's 2022 introduction of a luer lock silicone oil-free syringe for ophthalmic applications.Le Monde.frNovo Nordisk acquires medical device maker Biocorp for €154 millionNovo Nordisk acquired French medical device maker Biocorp for €154 million, first buying a 45.3% stake and then proposing a takeover bid at €35 per share. The deal targets Biocorp's Mallya connected sensor for insulin injection pens, which tracks daily doses. The acquisition aims to expand Novo Nordisk's connected solutions for chronic disease monitoring.GlobeNewswireNovo Nordisk enters exclusive negotiations to acquire a controlling stake in BIOCORP, to be followed by a tender offer on all remaining sharesNovo Nordisk entered exclusive negotiations to acquire BIOCORP's main shareholder BIO JAG's entire stake, representing 45.3% of share capital and 62.2% of voting rights, at €35 per share. The deal would be followed by a mandatory tender offer on all remaining shares, valuing BIOCORP at approximately €154 million. The Block Purchase is expected in Q3 2023, with the tender offer filed in September 2023.GlobeNewswireNovo Nordisk enters exclusive negotiations to acquire a controlling stake in BIOCORP, to be followed by a tender offer on all remaining sharesNovo Nordisk entered exclusive negotiations to acquire BIOCORP's main shareholder BIO JAG's entire stake, representing 45.3% of share capital and 62.2% of voting rights, at 35 euros per share. The deal would be followed by a mandatory tender offer on remaining shares, valuing the company at approximately 154 million euros. The Block Purchase is expected in Q3 2023, with the tender offer filed in September 2023.Business Wire BlogBIOCORP: Full-Year 2022 Financial Results and Outlook for 2023BIOCORP reported 2022 sales of €11.67 million, up 14% year-over-year, with operating expenses rising 20% to €12.58 million. The company posted a net loss of €0.65 million, though EBITDA remained positive at €42.9K. It expects a transition to recurring revenues from connected device sales in 2023.